Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

被引:9
作者
Fang, Rui [1 ,2 ]
Wang, Heng [1 ,2 ]
Li, Yang [1 ,2 ]
Liu, Yue-Ming [1 ,2 ]
Wei, Wen-Bin [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Beijing Tongren Hosp, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing 100730, Peoples R China
[3] Beijing Tongren Eye Ctr, Beijing, Peoples R China
[4] Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China
[5] Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China
[6] Minist Ind & Informat Technol, Med Artificial Intelligence Res & Verificat Lab, Beijing, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Uveal melanoma; Plaque radiotherapy; Tumor regression; Prognosis; CHOROIDAL MELANOMAS;
D O I
10.1186/s12886-021-01898-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. Methods Adult uveal melanoma patients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. Results A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). Conclusion Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.
引用
收藏
页数:9
相关论文
共 20 条
[1]   CHANGES IN HEIGHT OF CHOROIDAL MELANOMAS AFTER PLAQUE THERAPY [J].
ABRAMSON, DH ;
SERVODIDIO, CA ;
MCCORMICK, B ;
FASS, D ;
ZANG, E .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1990, 74 (06) :359-362
[2]   Epidemiological trends in uveal melanoma [J].
Andreoli, Michael T. ;
Mieler, William F. ;
Leiderman, Yannek I. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (11) :1550-1553
[3]  
AUGSBURGER JJ, 1987, OPHTHALMOLOGY, V94, P1173
[4]   Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project [J].
Bakhoum, Mathieu E. ;
Esmaeli, Bita .
CANCERS, 2019, 11 (08)
[5]   Does choroidal melanoma regression correlate with chromosome 3 loss after ruthenium brachytherapy? [J].
Chiam, Patrick J. T. ;
Coupland, Sarah E. ;
Kalirai, Helen ;
Groenewald, Carl ;
Heimann, Heinrich ;
Damato, Bertil E. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (07) :967-971
[6]  
CRUESS AF, 1984, OPHTHALMOLOGY, V91, P1716
[7]   Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma [J].
Kaiserman, I ;
Anteby, I ;
Chowers, I ;
Blumenthal, EZ ;
Kliers, I ;
Pe'er, J .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (07) :892-895
[8]   Changes in ultrasound findings in posterior uveal melanoma after ruthenium 106 brachytherapy [J].
Kaiserman, I ;
Anteby, I ;
Chowers, I ;
Blumenthal, EZ ;
Kliers, I ;
Pe'er, J .
OPHTHALMOLOGY, 2002, 109 (06) :1137-1141
[9]   Uveal melanoma: relatively rare but deadly cancer [J].
Kaliki, S. ;
Shields, C. L. .
EYE, 2017, 31 (02) :241-257
[10]   Clinical predictors of survival in metastatic uveal melanoma [J].
Lorenzo, Daniel ;
Maria Piulats, Josep ;
Ochoa, Maria ;
Arias, Luis ;
Gutierrez, Cristina ;
Catala, Jaume ;
Cobos, Estefania ;
Garcia-Bru, Pere ;
Dias, Bruno ;
Padron-Perez, Noel ;
Maria Caminal, Josep .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2019, 63 (02) :197-209